Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a biologic drug free severe asthma patients from High-Dose steroids?

NCT ID NCT07713498

Disease control Sponsor: Franciscus Gasthuis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study looks at whether people with severe asthma who start taking tezepelumab can safely lower their dose of inhaled corticosteroids. Researchers will track steroid use, asthma control, and flare-ups over 12 months in a real-world setting. The goal is to see if tezepelumab can reduce the need for steroids and their side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tezepelumab, a biologic drug, combined with tapering of inhaled corticosteroids
What this could lead to
If successful, this could show that tezepelumab allows people with severe asthma to use lower doses of inhaled steroids, reducing side effects while keeping asthma under control.
What could go wrong
This is a small, real-world study without a control group, so results may not prove cause and effect. Tapering steroids might lead to more asthma attacks in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 61 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All adult severe asthma patients that will start tezepelumab therapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 * Patient diagnosed with severe asthma according to the GINA guidelines * Written informed consent (AVG). * Eligibility and willingness to present during an asthma exacerbation at the Franciscus hospital. * Patient has received/or has been planned for at least one dose of tezepelumab * Sufficient understanding of the Dutch or English language Exclusion Criteria: * Other underlying inflammatory or auto-immune diseases that require OCS treatment, such as rheumatologic disease, IBD etc. * Pregnancy, because of the possible altered immunological status. * Participation in an interventional study that interferes with this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe asthma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Franciscus Gasthuis & Vlietland

    Rotterdam, South Holland, 3045PM, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.